LIVN

$62.67+1.24 (+2.03%)

Market OpenAs of Mar 17, 7:07 PM UTC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$62.67
Potential Upside
5%
Whystock Fair Value$65.81
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switz...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-19.24%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.05

Recent News

Zacks
Mar 13, 2026

Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)

The heavy selling pressure might have exhausted for LivaNova (LIVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy

LivaNova (LIVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 3, 2026

A Look At LivaNova (LIVN) Valuation After Earnings Show Growth Guidance And A Swing To Net Loss

Why LivaNova’s latest earnings and guidance matter for investors LivaNova (LIVN) is drawing attention after its latest update combined new 2026 revenue guidance of 6% to 7% constant currency growth, a projected 1% currency tailwind, and a full year 2025 net loss. For investors, that mix of top line growth guidance and bottom line pressure raises practical questions about how the business is performing today and what the new outlook might imply for risk, valuation, and expectations. See our...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 25, 2026

LivaNova Q4 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) executives highlighted double-digit revenue growth, operating margin expansion and stronger cash generation in 2025, while outlining expectations for more moderate top-line growth in 2026 driven by continued momentum in cardiopulmonary and epilepsy and ongoing investment in in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 25, 2026

LivaNova PLC (LIVN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

LivaNova PLC (LIVN) reports robust revenue growth and strategic progress, despite supply constraints and market challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.